These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10989724)

  • 41. [Effect of pefloxacin on immune response].
    Artsimovich NG; Nastoiashchaia NN; Navashin PS
    Antibiot Khimioter; 2001; 46(4):11-2. PubMed ID: 11550499
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New quinolones: similarities and differences].
    Levi GC
    AMB Rev Assoc Med Bras; 1989; 35(5):202-6. PubMed ID: 2486418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of ofloxacin, pefloxacin, and tobramycin on the hydrophobicity of Klebsiella pneumoniae].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1999 Feb; 48(1):28-30. PubMed ID: 11038674
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16.
    Lewin CS; Amyes SG
    J Med Microbiol; 1990 Jun; 32(2):83-6. PubMed ID: 1693968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pefloxacin in the treatment of severe infections in intensive care].
    Gritti G; Capuzzo M; Verri M; Nepoti ML; Nardini A
    Minerva Anestesiol; 1988 Sep; 54(9):367-72. PubMed ID: 3249624
    [No Abstract]   [Full Text] [Related]  

  • 46. [Bacterial endophthalmitis: treatment with a combination of fosfomycin and pefloxacin apropos of 9 cases].
    Salvanet-Bouccara A; Feys J; Koffi-Gue B; Fisch A; Cherifi M; Forestier F
    Bull Soc Ophtalmol Fr; 1989 Nov; 89(11):1281-6. PubMed ID: 2630133
    [No Abstract]   [Full Text] [Related]  

  • 47. Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections.
    Scaglione F; Scamazzo F; Arcidiacono MM; Cogo R; Monzani GP; Fraschini F
    J Chemother; 1995 Apr; 7(2):140-5. PubMed ID: 7666121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
    Fong IW
    Clin Invest Med; 1989 Feb; 12(1):44-9. PubMed ID: 2646054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carrier-mediated system for pefloxacin uptake in human monocytes.
    Mémin E; Panteix G; Revol A
    J Antimicrob Chemother; 1997 Aug; 40(2):263-8. PubMed ID: 9301993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pefloxacin treatment of meningitis caused by gram-negative bacteria.
    Segev S; Barzilai A; Rosen N; Joseph G; Rubinstein E
    Arch Intern Med; 1989 Jun; 149(6):1314-6. PubMed ID: 2730249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New possibilities in the care of surgical infections (personal experience with pefloxacin)].
    Rakovec S; Stanisavljević D
    Acta Chir Iugosl; 1989; 36 Suppl 2():748-50. PubMed ID: 2618497
    [No Abstract]   [Full Text] [Related]  

  • 52. [Sensitivity of Yersinia pseudotuberculosis to pefloxacin].
    Zaĭtseva EA; Shubin FN; Besednova NN
    Antibiot Khimioter; 1995 Jul; 40(7):22-4. PubMed ID: 8645054
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Focus on severe infections.
    Laupland KB; Paiva JA; Timsit JF
    Intensive Care Med; 2017 Jul; 43(7):1033-1036. PubMed ID: 28501950
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
    D'Antonio D; Iacone A; Fioritoni G; Betti S; Dell'Isola M; Quaglietta AM; Accorsi P; Pantalone V; Recchia A; Piergallini A
    Drugs Exp Clin Res; 1992; 18(4):141-6. PubMed ID: 1451644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Symposium "Abactal (pefloxacin)--new possibilities in antibacterial therapy"].
    Iakovlev VP
    Antibiot Khimioter; 1991 Nov; 36(11):52-3. PubMed ID: 1686542
    [No Abstract]   [Full Text] [Related]  

  • 56. [The in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections].
    Tunçkanat F; Yuluğ N
    Mikrobiyol Bul; 1988; 22(3):187-92. PubMed ID: 3252111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical efficacy of the new quinolones in lower respiratory infections.
    Davies BI; Maesen FP
    Chemioterapia; 1987 Jun; 6(2 Suppl):447-8. PubMed ID: 3509469
    [No Abstract]   [Full Text] [Related]  

  • 58. [Effectiveness of pefloxacin in the surgical clinic].
    Iakovlev VP; Blatun LA; Khlebnikov EP; Elagina LV; Puchkova LS
    Antibiot Khimioter; 1995 Aug; 40(8):43-5. PubMed ID: 8713438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pefloxacin in the treatment of gram-negative infections in patients with hematologic diseases.
    Micozzi A; Martino P; Raccah R; Girmenia C; Gentile G; Santilli S; Monarca B
    Haematologica; 1989; 74(6):583-5. PubMed ID: 2628241
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The place of fluoroquinolones in the treatment of bacterial infections].
    Iakovlev SV
    Antibiot Khimioter; 1999; 44(12):27-30. PubMed ID: 10687031
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.